Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dive into Moderna Therapeutics’ ambition to pull off the biggest IPO in biotech history at a time when the sector is having a hard time convincing investors of its promise. Then, STAT’s Casey Ross joins us to talk about his investigation into lockstep price increases for a pair of blockbuster drugs and the effects they have on patients. Finally, biopharma veteran and Yumanity Therapeutics CEO Dr. Tony Coles sits down to talk about his career, the future of neuroscience, and burner Twitter accounts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy